Natco Seeks To Trigger India CL Law By Asking Pfizer To OK HIV Copy
This article was originally published in PharmAsia News
India's Natco Pharma says it has asked U.S.-based Pfizer for permission to make and sell a generic version of its HIV drug, triggering a compulsory licensing law
You may also be interested in...
ViiV Healthcare Questions Natco's Ability To Make And Sell Selzentry In India; Stays Silent On Voluntary License Issue
MUMBAI - ViiV Healthcare - formed by GlaxoSmithKline Pharmaceuticals Plc and Pfizer Inc. in 2009 to work on a range of HIV/AIDS medications - struck back with a volley of questions to Natco Pharma Ltd., which had sought a voluntary license in December 2010 to manufacture generic versions of Selzentry
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
Third round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.